PP
PLX icon

Paloma Partners’s Protalix BioTherapeutics PLX Stock Holding History

Paloma Partners’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-79,442
Closed -$92.9K – 1569
2024
Q2 		$92.9K Buy
+79,442
New +$93.8K ﹤0.01% 1085

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Paloma Partners's PLX Position: Q3 2024 in Review

Paloma Partners sold out of Protalix BioTherapeutics (PLX) in Q3 2024, closing a stake of 79,442 shares — an estimated $92.9K sold.

Paloma Partners first reported a position in PLX in Q2 2024 and held it in 1 quarter. The position peaked at $92.9K in Q2 2024. 45 funds tracked by Wall St. Rank hold PLX as of Q3 2024.

  • Paloma Partners reported no remaining Protalix BioTherapeutics position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 79,442 Protalix BioTherapeutics shares in Q3 2024, an estimated $92.9K.
  • Paloma Partners first reported a position in Protalix BioTherapeutics in Q2 2024 and held it in 1 quarter.
  • Paloma Partners's Protalix BioTherapeutics position peaked at $92.9K in Q2 2024.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.